US Stock Insider Trading | Invivyd discloses 10 insider transactions on February 18

2026-02-20 18:41:20

On February 18, 2026, Invivyd (IVVD) disclosed 10 insider transactions. Executive Andersen Jill sold 34,900 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 18, 2026	Executive	Andersen Jill	February 18, 2026	Sell	34,900	1.58	55,100
February 18, 2026	Executive	Andersen Jill	February 17, 2026	Sell	32,800	1.54	50,500
February 18, 2026	Executive	Duke William E.	February 18, 2026	Sell	21,000	1.58	33,100
February 17, 2026	Executive	Duke William E.	February 17, 2026	Sell	19,700	1.54	30,300
February 17, 2026	Executive	Green Julie	February 17, 2026	Sell	19,700	1.54	30,300
February 18, 2026	Executive	Green Julie	February 18, 2026	Sell	21,000	1.58	33,100
February 18, 2026	Executive	Lee Timothy Edward	February 18, 2026	Sell	21,000	1.58	33,100
February 17, 2026	Executive	Lee Timothy Edward	February 17, 2026	Sell	19,700	1.54	30,300
February 18, 2026	Executive	Allen Robert D. III	February 18, 2026	Sell	19,400	1.58	30,600
February 17, 2026	Executive	Allen Robert D. III	February 17, 2026	Sell	18,200	1.54	28,000

[Company Information]

Invivyd, Inc. was incorporated in Delaware on June 3, 2020. The company is a late-stage enterprise dedicated to rapidly and permanently delivering antibody-based therapies to protect vulnerable populations from the destructive consequences of pandemic viruses, starting with SARS-CoV-2. Its proprietary INVYMAB platform combines cutting-edge viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB aims to facilitate the rapid and continuous development of new monoclonal antibodies (“MABs”) to keep pace with evolving viral threats.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.